Philips forms dental board as Philips stock costs EUR 21.72

Published on 10/09/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 4.36 billion, up 4.00 percent comparably. Philips stock stood at EUR 21.72 on October 9, 2026 after EUR 21.69.

Key points in brief

Philips established a 12-member Global Clinical Advisory Board for oral healthcare on October 8, 2026.
Second-quarter 2026 revenue reached EUR 4.36 billion, with comparable growth of 4.00 percent.
Philips stock stood at EUR 21.72 at Lang & Schwarz on October 9, 2026, plus 0.14 percent versus EUR 21.69.
Jefferies kept a Hold rating and a EUR 25.00 target ahead of the November 3, 2026 results.

Börsen-Editorial mit AEX-Kurstafeln und Händlern auf geschäftigem Handelsparkett — Koninklijke Philips N.V. (NL0000009538) illustriert Börsen-Editorial mit AEX-Kurstafeln und Händlern auf geschäftigem Amsterdamer Handelsparkett, Illustration mit AI erstellt.

Philips (ISIN NL0000009538) stock stood at EUR 21.72 at Lang & Schwarz on October 9, 2026 at 11:02 a.m. CEST, up 0.14 percent versus the prior close of EUR 21.69. On October 8, 2026, Philips announced a Global Clinical Advisory Board with 12 dental experts. The move adds a clinical-advisory layer to its Sonicare and oral-health innovation agenda.

Three dated milestones shape the story

On September 16, 2026, Philips said two Philips-led collaborations won ITEA Awards of Excellence. One project compressed fiber-optic sensing data more than 20 times while preserving performance in evaluated datasets.

On July 28, 2026, Philips reported second-quarter revenue of EUR 4.36 billion, up 4.00 percent on a comparable basis, and adjusted EBITA of EUR 717.00 million, according to De Belegger. The adjusted EBITA margin was 16.40 percent, including a EUR 186.00 million US tariff refund, so the quarter's margin requires careful interpretation.

What must the third quarter deliver?

Philips' next results are scheduled for November 3, 2026. Jefferies kept a Hold rating and a EUR 25.00 price target in its September 29, 2026 note, forecasting 3.00 percent operating revenue growth for the third quarter. That forecast sits at the lower end of Philips' 3.00 percent to 4.50 percent full-year comparable-growth range.

The comparison matters because adjusted EBITA of EUR 717.00 million benefited from the tariff refund, while comparable order intake declined 1.00 percent in the second quarter, according to De Belegger. For the upcoming report, order conversion and margin excluding one-off effects are therefore central operating tests.

Price holds near the recent report

At EUR 21.72, the Lang & Schwarz quote was EUR 0.03 above its October 8, 2026 prior close. The small move leaves the market focused on whether Philips can convert its health-technology pipeline into recurring revenue and cash generation rather than rely on a single tariff-related benefit.

The further course of trading is shown by the continuously updated real-time quote of Philips stock.